Open Actively Recruiting

Study of IMPT-314 in R/R Aggressive B-cell NHL


Brief Summary

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three cohorts of participants will be enrolled: 1) CAR T naïve after at least two or more prior lines of treatment, 2) CAR T experienced and 3) refractory disease or relapse within one year of first line therapy.

Up to approximately 90 patients (30 per cohort) will be enrolled in dose finding Phase 1 part of the study, which will determine the recommended phase 2 dose.

Phase 2 will enroll up to approximately 60 additional participants (20 per cohort) to evaluate further the safety and efficacy of IMPT-314.

IMPT-314 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a conditioning chemotherapy regimen consisting of fludarabine and cyclophosphamide, administered over 3 days.

Individual participants will remain in the active post-treatment period for approximately 2 years. Participants will continue in long-term follow-up for 15 years from treatment.

Primary Purpose
Study Type
Phase 1/Phase 2


Healthy Volunteers
Minimum Age
18 Years
Maximum Age

Inclusion Criteria:

  • Age 18 years or older
  • Willing and able to provide written informed consent
  • Histologically confirmed aggressive NHL, including the following types defined by the World Health Organization (WHO) 2017:
    • DLBCL
    • DLBCL arising from follicular lymphoma (Transformed FL)
    • Primary mediastinal (thymic) large B-cell lymphoma
    • High-grade large B-cell lymphoma with or without MYC and BCL2 and/or BCL6 rearrangement
    • Grade 3b follicular lymphoma/Large cell follicular lymphoma
  • Received at least 1 prior line of therapy. Prior therapy must have included:
    • Anti-CD20 monoclonal antibody
    • An anthracycline containing chemotherapy regimen
    • Participants with TFL must have received at least one of their prior lines of therapy after transformation to DLBCL
  • Relapsed or refractory disease, defined by the following:
    • Disease progression after last regimen (including salvage therapy after autologous stem cell transplantation [ASCT]). In participants who have only received front-line therapy, progression should be ≤12 months of initiating first-line therapy.
    • In patients who received two or more lines of therapy, refractory disease is defined as failure to achieve a CR to last line of therapy (including CAR T and/or salvage therapy).
    • In patients who received one line of therapy, refractory disease is defined as failure to achieve at least a PR after at least 4 cycles of therapy
  • At least 1 measurable lesion (the Lugano classification). Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Absolute neutrophil count (ANC) ≥ 1000/uL Other protocol-defined criteria apply.

Exclusion Criteria:

  • History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast) unless disease-free for at least 3 years. Participants who have received therapy for a prior malignancy within the prior 3 years, e.g., in the adjuvant setting, are not excluded
  • Active central nervous system (CNS) involvement by malignancy on magnetic resonance imaging (MRI) or by lumbar puncture. Participants with prior evidence of brain metastasis successfully treated at least 8 weeks prior to enrollment will not be excluded for participation if CNS disease is deemed stable at the time of study enrolment
  • History of cardiac lymphoma involvement
  • Ongoing or impending oncologic emergency (e.g., tumor mass effect, tumor lysis syndrome)
  • Received the following therapies in the specified time frame prior to enrollment/leukapheresis
    • Any systemic therapy within 2 weeks
    • Any systemic inhibitory/stimulatory immune checkpoint molecule therapy within 3 half-lives prior to enrollment (e.g., ipilimumab, nivolumab, pembrolizumab, atezolizumab, OX40 agonists, 4- 1BB agonists)
    • Fludarabine within 12 weeks
    • Alemtuzumab, bendamustine or antithymocyte globuline (ATG) within 6 months
    • Any T cell engager/bispecific antibody therapy such as CD20/CD3 or CD19/CD3 bispecific antibodies within 4 weeks
    • Any experimental therapy within 4 weeks or 5 half-lives (whichever is shorter)
  • Received radiation therapy within 3 weeks prior to enrollment
  • Experiencing non-hematologic toxicities due to prior therapy (stable and recovered to grade ≤ 1 or non- clinically significant toxicities such as alopecia are allowed)
  • History of allogeneic stem cell or solid organ transplantation
  • Receipt of autologous stem cell transplantation within 6 weeks prior to enrollment
  • History of prior genetically modified T cell therapy other than a product targeting CD19 with an FMC63-based CAR (e.g., axicabtagene ciloleucel (axi-cel, YESCARTA®), tisagenlecleucel (tisa-cel, KYMRIAH®), or lisocabtagene maraleucel (liso-cel, BREYANZI®). For all other CAR T cell therapy treatments, discussion with the Sponsor's Medical Monitor is required
  • Primary immunodeficiency
  • History of autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years. Participants who have other autoimmune condition(s) considered to be associated with underlying malignancy may be enrolled in the study after discussion with and approval of the Medical Monitor. Other protocol-defined criteria apply.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
Chris Hannigan
  • UCLA Santa Monica
  • UCLA Westwood
For Providers
For detailed technical eligibility, visit